<DOC>
	<DOCNO>NCT00313261</DOCNO>
	<brief_summary>The purpose study evaluate safety antiviral activity clevudine 30 mg QD treatment longer period ( 24 week ) patient chronically infected HBV .</brief_summary>
	<brief_title>Safety Efficacy Study L-FMAU Chronic HBV Patients L-FMAU-201 Placebo Group</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patients receive placebo LFMAU201 study 2 . Female childbearing potential negative serum ( betaHCG ) pregnancy test within 14 day start therapy . 3 . Patients able give write informed consent prior study start comply study requirement . 4 . Patients meet follow criterion completion Week 48 visit additional followup visit Weeks 54 60 : 1 ) receive additional therapy since completion 24week treatment clevudine 2 ) experience &gt; = 1 log10 decrease baseline HBV DNA Week 48 1 . Patient HBeAg seroconverted antiHBe last 2 consecutive visit ( one month apart ) LFMAU201 study . 2 . Patient currently receive antiviral , immunomodulatory corticosteroid therapy . 3 . Patient treat lamivudine , lobucavir , famciclovir , adefovir investigational nucleoside HBV infection cessation treatment LFMAU201 study . 4 . Patient history ascites , variceal hemorrhage hepatic encephalopathy . 5 . Patient coinfected HCV , HDV HIV . 6 . Patient clinical evidence cirrhosis hepatocellular carcinoma ( Â®Fetoprotein ) Evaluation base alphafetoprotein primarily . If alphafetoprotein level suggestive cirrhosis hepatocellular carcinoma , confirmation make ultrasonography etc . 7 . Patient pregnant breastfeeding . 8 . Patient unwilling use `` effective '' method contraception treatment period 3 month cessation therapy . For male , condom use . Females must surgically sterile ( via hysterectomy bilateral tubal ligation ) , postmenopausal use least medically acceptable barrier method contraception ( i.e. , IUD , barrier method supermicide abstinence ) 9 . Patient clinically relevant history abuse alcohol drug . 10 . Patient significant gastrointestinal , renal , hepatic ( decompensated ) , bronchopulmonary , neurological , cardiovascular , oncologic allergic disease . 11 . Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>